DelistingMay 22, 2026, 04:12 PM
XTL Biopharmaceuticals Faces Additional Nasdaq Delisting Basis
AI Summary
XTL Biopharmaceuticals received a letter from Nasdaq on May 18, 2026, notifying the company of an additional delisting basis due to its failure to timely file its Annual Report on Form 20-F for the year ended December 31, 2025. This adds to existing non-compliance issues regarding minimum $2.5 million stockholders' equity and minimum $1 bid price requirements. The Nasdaq Hearings Panel will consider this new deficiency in its decision regarding the company's continued listing. XTL intends to request an extended stay of the suspension of its securities by May 26, 2026.
Key Highlights
- Received Nasdaq letter on May 18, 2026, for failure to timely file 2025 Annual Report on Form 20-F.
- This constitutes an additional delisting basis under Nasdaq Listing Rule 5250(c)(1).
- Company already faces delisting for non-compliance with $2.5 million stockholders' equity.
- Also non-compliant with Nasdaq's minimum $1 bid price requirement.
- Nasdaq Hearings Panel will consider this new deficiency in its decision.
- XTL must present its views to the Panel in writing by May 26, 2026.
- Company intends to request an extended stay of suspension by May 26, 2026.
Price Impact
More from XTLB